Avenue Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 10.38 million compared to USD 3.55 million a year ago. Basic loss per share from continuing operations was USD 73.5002 compared to USD 122.2503 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.38 USD | -6.11% | -1.74% | -72.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-72.01% | 3.18M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- ATXI Stock
- News Avenue Therapeutics, Inc.
- Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023